Medical and Health Industry Weekly Report | "Hengjing Bio" Secures Over 200 Million Yuan in Series A Financing; "Sinofull Medical" Receives 128 Million Yuan in Series B+ Financing
In recent years, the healthcare industry has witnessed a continuous emergence of innovations and has developed into one of the most active sectors. 36Kr has witnessed and accompanied the growth of innovative enterprises in this field and brought professional voices to the industry.
For this reason, 36Kr has launched the "Healthcare Industry Weekly Report" column, which will be released regularly to provide readers with industry information from multiple perspectives such as capital, policies, finance, and new products.
Please check the Healthcare Industry Weekly Report for November 3. This weekly report includes financing news in the healthcare field this week.
Financing and Investment
- "Zhiyuan Shenlan" Completes Several Million Yuan Seed Round Financing
Beijing Zhiyuan Shenlan Technology Co., Ltd. has completed a seed round financing of several million yuan. This round of financing is led by InnoAngel Fund, with Tsinghua Alumni TMT Association Angel Fund and Zero2IPO Ventures as co-investors. The raised funds will be mainly used for the development of a functional-oriented biomolecular generative AI platform, the construction of an automated protein and polypeptide functional evolution platform, and the exploration of the commercial market. Zhiyuan Shenlan was founded in 2024 and focuses on data-driven biomolecular design and manufacturing, and was incubated by Meiga Technology.
- "Hengjing Bio" Receives Over 200 Million Yuan in Series A Financing
Hengjing Hechuang Biomedical Co., Ltd. has completed a total of approximately 250 million yuan in Series A and Series A+ financing. Among them, the institutional investor in Series A is Shanghai Zhangke Lingyi; Series A+ is mainly based on additional investment from old shareholders and self-raised funds by the founding team. The raised funds are mainly used for product clinical research, production project construction, and daily operations. Hengjing Bio was founded in 2021 and focuses on the industrialization of biosimilars, bioinnovative drugs, and biological products represented by insulin and GLP-1 receptor agonists. The founder, Dr. Fan Hao, completed postdoctoral research at the National Institutes of Health in the United States and has more than 20 years of experience in the research and development and large-scale production of biological products, leading the development of more than 10 large-scale production technologies for biosimilars. The core team of the company has an average working experience of more than 20 years in the pharmaceutical field and has established a complete industrialization team including R & D, production, quality control, and declaration.
- "Sinofull Medical" Receives 128 Million Yuan in Series B+ Financing
The enterprise "Sinofull Medical" in the field of precision medicine has recently completed a Series B+ financing of 128 million yuan. This round of financing is led by Hui Mei Capital, with Kaifeng Ventures and Nanwan Bai'ao as co-investors. The raised funds will be mainly used for the market promotion of digital PCR products, the development of related reagent product lines, and the large-scale expansion of overseas markets. Sinofull Medical was founded in 2018 and focuses on the industrialization of the third-generation droplet digital PCR equipment, providing fast, sensitive, accurate, and intelligent molecular diagnostic solutions.
- RuiPu ChenChuang Completes Over 100 Million Yuan in Series A Financing
RuiPu ChenChuang has completed a Series A financing of over 100 million yuan, invested by Lotus Pond Ventures. The funds will be used to promote the research and development and industrialization of cell therapy drugs. The company focuses on cell therapy for type 1 diabetes. According to the announcement of the Center for Drug Evaluation of the National Medical Products Administration (CDE), the IND application for "RGB-5088 Islet Cell Injection" submitted by Hangzhou RuiPu ChenChuang Technology Co., Ltd. has been accepted, which may become the first approved human pluripotent stem cell-derived islet cell therapy for diabetes in China.
- "Aoda Zhisheng" Completes Several Million Yuan in Series A Financing
Beijing Aoda Zhisheng Medical Technology Co., Ltd. announced the completion of a Series A financing of several million yuan exclusively invested by Qianhai Ark Health Fund, with Wasp Capital serving as the financial advisor for this round of financing. Aoda Zhisheng was founded in 2021 and the company focuses on providing robotic system solutions for minimally invasive cancer therapies. The founder and chairman of the company, Zhang Bo, is an associate professor at Waseda University and has been engaged in the research of software systems and artificial intelligence technology in the field of medical surgical robots for many years.
- "Dingzhi Dental" Completes Hundreds of Millions of Yuan in Series A Financing
Dingzhi Doctor Group (Shenzhen) Co., Ltd., a leading brand of dental implant experts in China, has completed a Series A financing of hundreds of millions of yuan. This round of financing is exclusively invested by Eight Roads Ventures. China Renaissance served as the exclusive financial advisor of Dingzhi Dental in this transaction. Dingzhi Dental was founded in 2019, integrating dental medical treatment, chain management, and supply chain, with its headquarters in Shanghai. The company's business is mainly dental implant services, while also offering multiple dental treatment service items such as orthodontics, aesthetic restoration, periodontal treatment, pediatric dentistry, and comprehensive dentistry.
- "Qinglan Jichuang" Completes Tens of Millions of Yuan in Angel Round Financing
Qinglan Jichuang Medical Equipment (Chengdu) Co., Ltd. recently announced the successful completion of an angel round series financing of tens of millions of yuan. This round of financing is led by Chengdu Science and Technology Innovation Investment Group, with Guanghua Wutong, Bangqin Capital, and Biocity Jingchuang and other well-known investment institutions as co-investors. Groad Capital will serve as the financial advisor for the subsequent financing. The raised funds will be mainly used to promote the commercialization process of the world's first integrated platform of hard and soft endoscopes Cindigo Ori™ and its core endoscope types, and to further improve the product layout of the full range of soft and hard endoscopes of Cindigo Ori™.
- "Saiyun Bio" Completes Several Million Yuan in Angel Round Financing
Saiyun Biotech (Chengdu) Co., Ltd. has successfully completed an angel round financing of several million yuan. This round of financing is jointly led by Life Park Venture Capital Fund and a well-known fund, with InnoAngel Fund and other entities as co-investors. Saiyun Bio is committed to the development of international cutting-edge delivery vector technology and related drug innovation therapies, aiming to provide a new means for precise drug delivery.
- "Huiyue Medical" Completes Several Million Yuan in Angel Round Financing
Suzhou Huiyue Medical Technology Co., Ltd., positioned as an intelligent natural orifice transluminal endoscopic surgery robot, announced the completion of an angel round financing of several million yuan led by Lotus Pond Ventures. This round of financing will be used for the company's product type inspection and clinical trials. Sunstar Capital served as the exclusive financial advisor for this round of financing. Huiyue Medical was established in the Suzhou Industrial Park in 2022, focusing on the research and development, production, and sales of artificial intelligence surgical robots. The core technology of the company comes from the scientific and technological achievements of the national key research and development plan, and all the core components of the products are independently developed.
Focus Analysis
- Hengrui Medicine Considers "Financing in Overseas Capital Markets", Taking Another "Bold" Step in Its Overseas Strategy | Focus Analysis
Hengrui Medicine may go for a secondary listing in Hong Kong, which is probably one of the most concerned news in the pharmaceutical circle at the end of October. On the same day as the release of the third quarterly report, the market spread the news that Hengrui Medicine will go public in Hong Kong and raise at least 2 billion US dollars (about 14 billion yuan). In the A-share market, as there is almost no traditional pharmaceutical company that can match it, Hengrui Medicine enjoys a high premium as an industry leader. However, a listing in Hong Kong may not bring such a return to Hengrui Medicine. According to the current performance of the "A+H" premium rate, among the companies listed in both places, basically no company's Hong Kong stock value exceeds that of the A-share. If it really goes for a secondary listing in Hong Kong, it is likely to have a reverse impact on the A-share stock price and trading.
Therefore, on the day when the financing news was spread, Hengrui Medicine's share price dropped by up to 5.7% at one point, and its market value evaporated by nearly 13 billion yuan. Hengrui Medicine had to come forward to respond: Recently, the company has indeed carried out research and consultation and other preliminary work on matters such as financing in overseas capital markets, but "the specific plan has not yet been determined". The main reason is to deepen the "scientific and technological innovation and international development strategy".
The international exploration of Hengrui Medicine can basically be regarded as a typical case of the "big turn" of traditional Chinese pharmaceutical companies. Initially, Hengrui Medicine still believed more in its own strength. It tried to establish overseas subsidiaries by itself and also acquired Chinese innovative pharmaceutical companies whose products were being declared for listing overseas. At this stage, the tuition paid was greater than the harvest.
However, this year, many actions of Hengrui Medicine in going overseas have gradually reversed the market's impression that it has been "suffering losses all the time". From the authorization of the GLP-1 pipeline to ignite the enthusiasm of domestic innovative drugs for going overseas to the recent introduction of a former senior executive of Johnson & Johnson as the "Head of Global Development Affairs", Hengrui Medicine has continuously shown the humble attitude of an established pharmaceutical company actively moving towards a new world... (Click here for more details)
Editor: Hu Xiangyun